Edesa Biotech Inc (EDSA)

$4.14 0.00 (N/A)
Market Cap 39.91M
Revenue (ttm) 0.00
Net Income (ttm) -7.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 41,300
Avg Vol 69,444
Day's Range N/A - N/A
Shares Out 9.64M
Stochastic %K 24%
Beta 1.05
Analysts Strong Sell
Price Target $16.33

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology
Sector: Healthcare
Phone: 289 800 9600
Address:
100 Spy Court, Markham, Canada
AllmightyDollah
AllmightyDollah Sep. 18 at 11:22 PM
$EDSA Any question why no FDA go ahead on eb06? Just gonna slow play it in Canada for now huh. Pardeep Kumar the ass man.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 18 at 7:30 PM
$EDSA
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 18 at 2:22 PM
$EDSA Well. It’s Friday and we all know no other stock is as depressing as Turdesa on a Friday. I suspect a close in the $3S just to truly stick it to shareholders.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 18 at 1:36 PM
$EDSA Just another week goes by with DEI paychecks getting paid. No news. Nothing. It’s always nothing at old Turdesa. This part time CEO should have been fired years ago.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 17 at 9:36 PM
$EDSA Turdesa Biotech announced first patient dosed with Eb06. Only 3 years late but who cares? Paychecks kept flowing huh?!
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 17 at 1:52 PM
$EDSA Spread is back. Are we going for reversal?
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 17 at 1:29 PM
$EDSA can we make it 11 days in a row red? Go Canada!!!
0 · Reply
EdV3
EdV3 Sep. 17 at 1:12 AM
$EDSA what is company doing man....like fr who were the funds who invested in the last round? What kind of due diligence did they do? Smh.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 11:40 PM
$EDSA
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 10:57 PM
$EDSA Par’s other DEI hottie. Free paycheck. Does nothing.
0 · Reply
Latest News on EDSA
Edesa Biotech 3.87M share Spot Secondary priced at $5.50

2026-08-20T10:11:01.000Z - 4 weeks ago

Edesa Biotech 3.87M share Spot Secondary priced at $5.50

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Aug 19, 2026, 10:20 PM EDT - 4 weeks ago

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Edesa Biotech announces offering of common stock and warrants, no amount given

2026-08-19T20:05:28.000Z - 4 weeks ago

Edesa Biotech announces offering of common stock and warrants, no amount given

Edesa Biotech Announces Proposed Public Offering

Aug 19, 2026, 4:01 PM EDT - 4 weeks ago

Edesa Biotech Announces Proposed Public Offering

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Aug 13, 2026, 4:15 PM EDT - 5 weeks ago

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech files to sell 729,241 common shares for holders

2026-07-02T21:05:18.000Z - 2 months ago

Edesa Biotech files to sell 729,241 common shares for holders

Edesa Biotech reinstated with a Buy at Brookline

2026-06-29T19:50:30.000Z - 2 months ago

Edesa Biotech reinstated with a Buy at Brookline

Edesa Biotech announces $3.5M private placement

2026-06-11T13:27:38.000Z - 3 months ago

Edesa Biotech announces $3.5M private placement

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Jun 11, 2026, 9:15 AM EDT - 3 months ago

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Jun 5, 2026, 9:20 AM EDT - 3 months ago

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Edesa Biotech Inc trading resumes

2026-05-19T13:40:50.000Z - 4 months ago

Edesa Biotech Inc trading resumes

Edesa Biotech Inc trading halted, volatility trading pause

2026-05-19T13:35:48.000Z - 4 months ago

Edesa Biotech Inc trading halted, volatility trading pause

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

May 19, 2026, 9:15 AM EDT - 4 months ago

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

May 14, 2026, 4:30 PM EDT - 4 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

Edesa Biotech Inc trading halted, volatility trading pause

2026-04-28T14:26:55.000Z - 4 months ago

Edesa Biotech Inc trading halted, volatility trading pause

Edesa Biotech Inc trading resumes

2026-04-28T14:20:13.000Z - 4 months ago

Edesa Biotech Inc trading resumes

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Mar 31, 2026, 4:20 PM EDT - 5 months ago

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech provides update on EB06 clinical study

2026-03-26T13:37:21.000Z - 5 months ago

Edesa Biotech provides update on EB06 clinical study

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Mar 26, 2026, 9:15 AM EDT - 5 months ago

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech reports additional results from Phase 3 paridiprubart study

2026-02-24T14:20:13.000Z - 6 months ago

Edesa Biotech reports additional results from Phase 3 paridiprubart study

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Feb 24, 2026, 9:15 AM EST - 6 months ago

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Edesa Biotech reports Q1 EPS (28c), consensus (45c)

2026-02-13T21:25:18.000Z - 7 months ago

Edesa Biotech reports Q1 EPS (28c), consensus (45c)

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Feb 13, 2026, 4:20 PM EST - 7 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Edesa Biotech Reports Fiscal Year 2025 Results

Dec 12, 2025, 4:20 PM EST - 9 months ago

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Oct 31, 2025, 4:30 PM EDT - 10 months ago

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech announces Phase 3 study of paridiprubart met primary endpoint

2025-10-28T11:55:48.000Z - 10 months ago

Edesa Biotech announces Phase 3 study of paridiprubart met primary endpoint

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Oct 28, 2025, 7:45 AM EDT - 10 months ago

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Aug 8, 2025, 4:35 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Edesa Biotech files $150M mixed securities shelf

2025-07-25T20:50:18.000Z - 1 year ago

Edesa Biotech files $150M mixed securities shelf

Edesa Biotech assumed with a Buy at H.C. Wainwright

2025-06-27T14:35:08.000Z - 1 year ago

Edesa Biotech assumed with a Buy at H.C. Wainwright

Edesa Biotech initiated with a Buy at Lucid Capital

2025-05-23T10:55:53.000Z - 1 year ago

Edesa Biotech initiated with a Buy at Lucid Capital

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFO

2025-04-04T20:20:09.000Z - 1 year ago

Edesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFO

Edesa Biotech Announces Chief Financial Officer Transition

Apr 4, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Announces Chief Financial Officer Transition

Edesa Biotech files to sell 7.81M common shares for holders

2025-03-04T21:36:26.000Z - 1 year ago

Edesa Biotech files to sell 7.81M common shares for holders

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 14, 2025, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 7:00 AM EST - 1 year ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal Year 2024 Results

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech's Founder Makes Strategic Investment in the Company

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Sep 13, 2024, 7:38 PM EDT - 2 years ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Aug 9, 2024, 4:20 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Jun 24, 2024, 8:20 AM EDT - 2 years ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Edesa Biotech to Participate in Upcoming Investor Conferences

Apr 2, 2024, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 21, 2024, 4:30 PM EDT - 2 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 7, 2024, 8:45 AM EST - 2 years ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Jan 4, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Edesa Biotech Reports Fiscal Year 2023 Results

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Nov 20, 2023, 4:05 PM EST - 2 years ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 25, 2023, 9:10 AM EDT - 2 years ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:15 PM EDT - 2 years ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 12, 2023, 12:10 PM EDT - 2 years ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Edesa Biotech Announces One-for-Seven Reverse Share Split

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Sep 28, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Aug 9, 2023, 4:15 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jul 26, 2023, 9:00 AM EDT - 3 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 28, 2023, 7:55 AM EDT - 3 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 27, 2023, 8:15 AM EDT - 3 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Jun 15, 2023, 8:00 AM EDT - 3 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

May 11, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Edesa Biotech to Participate in Swiss Biotech Day

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Edesa Biotech to Participate in Swiss Biotech Day

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Apr 4, 2023, 8:45 AM EDT - 3 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 23, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

AllmightyDollah
AllmightyDollah Sep. 18 at 11:22 PM
$EDSA Any question why no FDA go ahead on eb06? Just gonna slow play it in Canada for now huh. Pardeep Kumar the ass man.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 18 at 7:30 PM
$EDSA
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 18 at 2:22 PM
$EDSA Well. It’s Friday and we all know no other stock is as depressing as Turdesa on a Friday. I suspect a close in the $3S just to truly stick it to shareholders.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 18 at 1:36 PM
$EDSA Just another week goes by with DEI paychecks getting paid. No news. Nothing. It’s always nothing at old Turdesa. This part time CEO should have been fired years ago.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 17 at 9:36 PM
$EDSA Turdesa Biotech announced first patient dosed with Eb06. Only 3 years late but who cares? Paychecks kept flowing huh?!
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 17 at 1:52 PM
$EDSA Spread is back. Are we going for reversal?
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 17 at 1:29 PM
$EDSA can we make it 11 days in a row red? Go Canada!!!
0 · Reply
EdV3
EdV3 Sep. 17 at 1:12 AM
$EDSA what is company doing man....like fr who were the funds who invested in the last round? What kind of due diligence did they do? Smh.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 11:40 PM
$EDSA
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 10:57 PM
$EDSA Par’s other DEI hottie. Free paycheck. Does nothing.
0 · Reply
Treb3k
Treb3k Sep. 16 at 10:42 PM
$EDSA we are in deep trouble
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 8:19 PM
$EDSA Par’s favorite DEI hottie. Free paycheck and does nothing.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 7:59 PM
$EDSA Low of day close! 10 Straight days red!!! You can do it you Canadian pos scam!
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 7:42 PM
$EDSA
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 7:22 PM
$EDSA So has Eb06 trial started lol? Of course not. Company hasn’t run a trial in 3 years. Posting rehashed news and lies about trials starting. Stock price should be $0. Maybe we get there. It’s really a sick joke.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 6:58 PM
$EDSA Bet you this Canadian scam can easily go back to $1 in coming weeks. You can see there is absolutely no buyers. Easiest short in bio. I could see Velan selling at a loss soon just for the Tax harvesting. Look at their winner $PRAX Wild they didn’t sell their position here between $15-$20 especially owning 35% of the company at literally $1 per share. Canada just faxks up everything. Such a shitehole of a country in every aspect.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 5:57 PM
$EDSA Can the scam close low of day and make it 10 red days in a row? Let’s make a -10% day. Easiest short on bio with a scam CEO.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 5:47 PM
$EDSA $20 to $3.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 5:44 PM
$EDSA
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 5:38 PM
$EDSA Scamming CEO of the year goes to.
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 4:37 PM
$EDSA
0 · Reply
AllmightyDollah
AllmightyDollah Sep. 16 at 2:59 PM
$EDSA Can some of you who don’t have this account blocked get it banned? It’s a heel account that has gone too far. It needs to go. It’s not fair to those of investors still holding this stock. Thanks.
0 · Reply